Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Completed No phase listed Observational Results available

Long-term Effect of Lanthanum Carbonate on Bone

NCT00557323
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Lanthanum carbonate
Drug
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Lynwood, California • Torrance, California • Springfield, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
125
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Not applicable Interventional

Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction

NCT05674786
View directory record Official record
Conditions
Other Disorders of Vestibular Function, Bilateral, Bilateral Vestibular Deficiency (BVD), Gentamicin Ototoxicity, Labyrinth Diseases, Vestibular Diseases, Sensation Disorders, Bilateral Vestibular Hypofunction, Bilateral Vestibulopathy, Aminoglycoside Ototoxicity
Interventions
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting No phase listed Observational

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

NCT06640010
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

Side Effects of Pulmonary Hypertension Medications

NCT01571713
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Not applicable Interventional

Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

NCT02428660
View directory record Official record
Conditions
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, CYP2D6 Polymorphism
Interventions
Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
Genetic · Other
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

Lead Registry for Optim Leads

NCT01722188
View directory record Official record
Conditions
Optim Lead Insulation Related Adverse Events
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
14,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
245
States / cities
Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days

NCT00616018
View directory record Official record
Conditions
Drug Induced Liver Injury
Interventions
acetaminophen
Drug
Lead sponsor
Kennon Heard
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

NCT07291232
View directory record Official record
Conditions
Obesity
Interventions
ABBV-295, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Terminated Phase 3 Interventional Results available

UNITE Study: Understanding New Interventions With GBM ThErapy

NCT03419403
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Steroid eye drops, Vasoconstrictor eye drops, Cold compress, Ophthalmic steroid ointment, Depatuxizumab mafodotin, Temozolomide, Radiation
Drug · Other · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846
View directory record Official record
Conditions
Non Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Vedotin, Docetaxel
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 4 Interventional

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

NCT00663442
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
6 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

NCT03215940
View directory record Official record
Conditions
Chronic Pain, Widespread
Interventions
Delta-9-Tetrahydrocannabinol, Cannabidiol, Placebos
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational Results available

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

NCT04682587
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, Avelumab, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens

NCT02625155
View directory record Official record
Conditions
Target Drug-related Adverse Events
Interventions
Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
Other
Lead sponsor
InSource Diagnostics
Industry
Eligibility
12 Years and older
Enrollment
14,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Tazewell, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

NCT06862648
View directory record Official record
Conditions
Stress Urinary Incontinence (SUI)
Interventions
Acoustic Stimulation Therapy Device, Sham Acoustic Stimulation Therapy Device
Device
Lead sponsor
Acoustic Wave Cell Therapy, Inc.
Industry
Eligibility
22 Years to 77 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Lakeland, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 23, 2026, 8:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854
View directory record Official record
Conditions
Immunoglobulin Light Chain (AL) Amyloidosis
Interventions
ABBV-383 (Etentamig)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 8:38 PM EDT
Active, not recruiting Not applicable Interventional

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions
Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
Other · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 23, 2026, 8:38 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Blood Vessels of the Heart

NCT00001638
View directory record Official record
Conditions
Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 23, 2026, 8:38 PM EDT
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 23, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

NCT01461824
View directory record Official record
Conditions
Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 23, 2026, 8:38 PM EDT